{"nctId":"NCT00309387","briefTitle":"Collaborative Italian-American Clinical Trial of Nutritional Supplements and Age-related Cataract (CTNS)","startDateStruct":{"date":"1995-05"},"conditions":["Cataract"],"count":1020,"armGroups":[{"label":"Centrum","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: Centrum"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Centrum","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical and photographic diagnosis of early or no age-related cataract\n* Participants with early cataract must have at least one eligible eye with VA score 20/32 or better\n* Participants with no cataract must have VA score 20/32 or better in both eyes.\n\nExclusion Criteria:\n\n* Advanced cataract\n* Bilateral aphakia or pseudophakia\n* Any ocular disease or condition that might complicate the future evaluation of cataract\n* Regular use of nutritional supplements\n* Failure to take at least 75% of run-in medication\n* Cancer with evidence of recurrence in the past 5 years\n* Major cerebral or cardiovascular events in past 12 months\n* Current participation to other clinical trials\n* Any condition likely to prevent adherence to CTNS follow-up schedule","healthyVolunteers":true,"sex":"ALL","minimumAge":"55 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Showing Development or Progression of Age-related Cataract or Undergoing Cataract Surgery During Follow-up","description":"number of participants in whom any of the following occur in at least one eligible eye during follow-up: cataract surgery; nuclear opacity: a 1.5 U increase in opalescence from baseline; cortical opacity: a 10% increase in area within a standard 5 mm circle area of the lens from baseline; posterior subcapsular opacity: a 5% increase in area within a standard 5 mm circle area of the lens from baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"227","spread":null},{"groupId":"OG001","value":"255","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Showing Development or Progression of Nuclear Lens Opacities","description":"number of participants with a 1.5 U increase in nuclear opalescence from baseline in at least one eligible eye during follow-up","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"118","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Showing Development or Progression of Cortical Lens Opacities","description":"Number of participants with a 10% increase in area of cortical opacity within a standard central 5 mm circle of the lens from baseline in at least one eligible eye during follow-up","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"118","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Showing Development or Progression of Posterior Subcapsular Opacities","description":"Number of participants with a 5% increase in area of posterior subcapsular opacity within a standard central 5 mm circle of the lens from baseline in at least one eligible eye during follow-up","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Undergoing Cataract Surgery","description":"number of participants undergoing cataract surgery in at least one eligible eye during follow-up","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Decrease in Visual Acuity","description":"Number of participants with a decrease in best corrected visual acuity score from baseline of \\> 15 letters in at least one eligible eye during follow-up","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"144","spread":null},{"groupId":"OG001","value":"139","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":363,"n":510},"commonTop":["upset stomach","other","skin rash","increased weight"]}}}